Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic, T-Cell 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Rituximab 19zanubrutinib 13acalabrutinib 11Magnetic Resonance Spectroscopy 11obinutuzumab 10Specimen Handling 10Cyclophosphamide 10Biopsy 9glofitamab 8Bendamustine Hydrochloride 8pirtobrutinib 7fludarabine 7venetoclax 6orelabrutinib 6Lenalidomide 5Cytarabine 5ibrutinib 4fludarabine phosphate 3Immunotherapy, Adoptive 3CT-P10 3tafasitamab 2polatuzumab vedotin 2loncastuximab tesirine 2brexucabtagene autoleucel 2Whole-Body Irradiation 2Therapeutics 2Prednisone 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Mantle-Cell × Lisaftoclax × Clear all
NCT07272499 2025-12-09

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Ruijin Hospital

Phase 2 Recruiting
25 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡